Strengthening the Delivery and Improving Outcomes of Drug-Resistant TB Treatment through Rational Medication Use Review

H. Fomundam, A. Maranga, W. Jassat, N. Njeka
{"title":"Strengthening the Delivery and Improving Outcomes of Drug-Resistant TB Treatment through Rational Medication Use Review","authors":"H. Fomundam, A. Maranga, W. Jassat, N. Njeka","doi":"10.4172/2376-0419.1000192","DOIUrl":null,"url":null,"abstract":"Introduction: A Rational Medication Use Review was conducted in health facilities in five high burden provinces (KwaZulu Natal, Western Cape, Eastern Cape, Gauteng and North West) that account for 77% of MDR-TB cases and 92% of XDR-TB in South Africa. Methodology: A purposive sampling of health facilities was done and stratified to represent different models of DR-TB service providers including centralized sites, decentralized sites, and satellite sites. Records for review were selected randomly among patients who initiated treatment between October 2011 and December 2012 and descriptive analysis conducted. Results: The review involved 139 patients (76.3% MDR-TB and 17.3% XDR-TB). 76.3% of them had a pretreatment DST and this was used for regimen selection. Renal function monitoring for dose adjustment was poor although baseline serum creatinine values were available on record for 69.1% of the patients. There was a high degree of missed doses with 66.7% of the patients having at least one missed dose. Co-morbid conditions were common with 66.2%, 13.0% and 5.8% of the patents with HIV, hypertension and seizure disorders respectively. Only 30.2% of the MDR-TB patents and 50% of the XDR-TB patients had been assessed for adverse drug reactions during the intensive phase although 125 episodes of ADRs were on record. Serum creatinine monitoring was not consistent (only 22.3% of patients had monthly values) although 16.1% of the patients had levels that would have required dose adjustments that were not done. Conclusion: There are many factors related to the patient, drug therapy, health care providers, and the health system that may adversely influence DR-TB treatment outcomes and patient safety. These can be detected early through regular rational medication use review and institutionalization of the process. This however requires a multidisciplinary approach with involvement of levels of the health system and various institutions involved TB in medication use.","PeriodicalId":16700,"journal":{"name":"Journal of Pharmaceutical Care & Health Systems","volume":"151 1","pages":"1-7"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Care & Health Systems","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2376-0419.1000192","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: A Rational Medication Use Review was conducted in health facilities in five high burden provinces (KwaZulu Natal, Western Cape, Eastern Cape, Gauteng and North West) that account for 77% of MDR-TB cases and 92% of XDR-TB in South Africa. Methodology: A purposive sampling of health facilities was done and stratified to represent different models of DR-TB service providers including centralized sites, decentralized sites, and satellite sites. Records for review were selected randomly among patients who initiated treatment between October 2011 and December 2012 and descriptive analysis conducted. Results: The review involved 139 patients (76.3% MDR-TB and 17.3% XDR-TB). 76.3% of them had a pretreatment DST and this was used for regimen selection. Renal function monitoring for dose adjustment was poor although baseline serum creatinine values were available on record for 69.1% of the patients. There was a high degree of missed doses with 66.7% of the patients having at least one missed dose. Co-morbid conditions were common with 66.2%, 13.0% and 5.8% of the patents with HIV, hypertension and seizure disorders respectively. Only 30.2% of the MDR-TB patents and 50% of the XDR-TB patients had been assessed for adverse drug reactions during the intensive phase although 125 episodes of ADRs were on record. Serum creatinine monitoring was not consistent (only 22.3% of patients had monthly values) although 16.1% of the patients had levels that would have required dose adjustments that were not done. Conclusion: There are many factors related to the patient, drug therapy, health care providers, and the health system that may adversely influence DR-TB treatment outcomes and patient safety. These can be detected early through regular rational medication use review and institutionalization of the process. This however requires a multidisciplinary approach with involvement of levels of the health system and various institutions involved TB in medication use.
通过合理用药审查加强耐药结核病治疗的交付和改善结果
引言:在五个高负担省份(夸祖鲁-纳塔尔省、西开普省、东开普省、豪登省和西北部)的卫生机构进行了合理用药审查,这些省份占南非耐多药结核病病例的77%和广泛耐药结核病病例的92%。方法:对卫生设施进行了有目的的抽样,并进行了分层,以代表耐药结核病服务提供者的不同模式,包括集中式站点、分散式站点和卫星站点。在2011年10月至2012年12月间开始治疗的患者中随机选取病历进行回顾性分析。结果:共纳入139例患者,其中76.3%为耐多药结核病,17.3%为广泛耐药结核病。76.3%的患者进行了预处理DST,用于方案选择。尽管69.1%的患者有记录的基线血清肌酐值,但对剂量调整的肾功能监测较差。漏给剂量程度高,66.7%的患者至少漏给一次剂量。合并HIV、高血压和癫痫的患者分别占66.2%、13.0%和5.8%。虽然有125次不良反应记录,但在强化阶段,只有30.2%的耐多药结核病患者和50%的广泛耐药结核病患者进行了药物不良反应评估。血清肌酐监测不一致(只有22.3%的患者有每月的值),尽管16.1%的患者有需要调整剂量的水平,但没有进行调整。结论:与患者、药物治疗、卫生保健提供者和卫生系统相关的许多因素可能对耐药结核病治疗结果和患者安全产生不利影响。这些可以通过定期的合理用药审查和制度化的过程及早发现。然而,这需要一种多学科方法,涉及各级卫生系统和涉及结核病药物使用的各种机构。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信